| ¿µ¹® | protein | ÇÑ±Û | ´Ü¹éÁú |
|---|---|---|---|
| ¼³¸í | ź¼Ò, ¼ö¼Ò, »ê¼Ò, Áú¼Ò, ȲÀ» ÇÔÀ¯Çϰí ÀÖ´Â À¯±âÈÇÕ¹°·Î, ¸ðµç ¼¼Æ÷ÀÇ ¿øÇüÁúÀ» ÀÌ·ç°í ÀÖ´Â ±âº» ±¸¼º¹°ÁúÀÌ´Ù. ´Ü¹éÁúÀº ±× ´ÜÀ§ÀÎ ¾Æ¹Ì³ë»êµéÀÌ ÆéƼµå°áÇÕ¿¡ ÀÇÇØ °áÇյǾî ÀÖÀ¸¸ç, º¸Åë 20°³ÀÇ ¾Æ¹Ì³ë»êµéÀÌ ´Ù¸¥ ¼ø¼¿Í Á¶¼ºÀ» °¡Áö°í ¹è¿µÇ¾î, µ¶Æ¯ÇÑ ÇϳªÀÇ ´Ü¹éÁúÀ» Çü¼ºÇÏ°Ô µÈ´Ù. |
||
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
|---|---|
| MBP | major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl... |
| RP | radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;... |
| LAI assay | Leukocyte Adherence Inhibition assay |
| AR | absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista... |
| DA | Diffuse adherence |
|---|---|
| EAF | EPEC adherence factor |
| IA | Immune Adherence |
| IAHA | Immune adherence hemagglutination |
| LAI | Leucocyte adherence inhibition |
| adherence | Refers to the ability of bacteria adhere (stick) to host surfaces. (09 Oct 1997) |
|---|---|
| adherence syndrome | <syndrome> Restriction action of an ocular muscle owing to adhesions between the muscle and its fascial sheath. (05 Mar 2000) |
| red cell adherence phenomenon | A phenomenon manifested by the adherence of antigen-antibody-complement complex to "indicator cells" (microorganisms, platelets, leukocytes, or erythrocytes), the reaction being sensitive and specific for the antigen and antibody in the complex. Synonym: erythrocyte adherence phenomenon, immune adherence phenomenon, red cell adherence phenomenon. (05 Mar 2000) |
| red cell adherence test | The diagnostic application of the immune adhesion phenomenon. Synonym: erythrocyte adherence test, immune adhesion test, red cell adherence test. (05 Mar 2000) |
| guideline adherence | Conformity in fulfilling or following official, recognised, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards. (12 Dec 1998) |
| immune adherence | The binding of antigen-antibody complexes or cells coated with antibodies or complement to cells bearing the appropriate complement or Fc receptors. (05 Mar 2000) |
| immune adherence phenomenon | A phenomenon manifested by the adherence of antigen-antibody-complement complex to "indicator cells" (microorganisms, platelets, leukocytes, or erythrocytes), the reaction being sensitive and specific for the antigen and antibody in the complex. Synonym: erythrocyte adherence phenomenon, immune adherence phenomenon, red cell adherence phenomenon. (05 Mar 2000) |
| immune adherence reaction | A method for the detection of very small quantities of antibody in which the antigen-antibody-complement complex adheres to indicator cells, usually primate erythrocytes or nonprimate blood platelets. The reaction is dependent on the number of bound c3 molecules on the c3b receptor sites of the indicator cell. (12 Dec 1998) |
| erythrocyte adherence phenomenon | A phenomenon manifested by the adherence of antigen-antibody-complement complex to "indicator cells" (microorganisms, platelets, leukocytes, or erythrocytes), the reaction being sensitive and specific for the antigen and antibody in the complex. Synonym: erythrocyte adherence phenomenon, immune adherence phenomenon, red cell adherence phenomenon. (05 Mar 2000) |
| leukocyte adherence assay test | A test to detect the ability of leukocytes to adhere to bacteria, performed in vitro using nylon fibres to measure adherence. (05 Mar 2000) |
| leukocyte adherence inhibition test | Test for cell-mediated antitumour immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumours of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumour-bearing patients block the lai reaction of their own leukocytes or those of other patients with the same type of tumour. (12 Dec 1998) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|